First Cannabinoid-Based Transdermal Patch for Chronic Pain Is Ready for Release

First Cannabinoid-Based Transdermal Patch for Chronic Pain Is Ready for Release

The first batch of the Chronic Pain CBIS Transdermal Patch will soon be released, offering a cannabinoid-based alternative to people around the globe who self-medicate for fibromyalgia and other chronic pain conditions, Cannabis Science has announced.

In November 2016, the company announced the development of two new medications for pain relief in people with fibromyalgia, neuropathy, diabetic nerve pain, back strains, and other pain-related conditions. These pain relievers correspond to transdermal adhesive patches that deliver a certain dose of medication into the bloodstream by absorption through the patient’s skin.

The first CBIS Transdermal Patch contains high-potency cannabinoid (CBD) extract, the second major cannabinoid in marijuana after tetrahydrocannabinol (THC). CBD has all the anti-inflammatory and pain-relieving properties without any psychoactive effects, and research has demonstrated that it can be an effective treatment for inflammatory pain. Some studies have even demonstrated that CBD might outperform traditional pain medication in some cases.

“The CBIS medicated adhesive transdermal patch is placed on the skin to deliver a specific dose of cannabinoid medications into the bloodstream,” Allen Herman, chief medical officer of Cannabis Science, said in a press release. “Self-medicating patients have been reporting promoted healing effects to specific injured areas of the body experiencing chronic pain.

Herman said the transdermal patch has an advantage over other types of medication delivery, including oral, topical, intravenous, and intramuscular, because it can “provide a controlled release of the medication into the patient, usually through a porous membrane covering a reservoir of medication or body heat that melts thin layers of high potency cannabinoid formulations embedded in the adhesive; the medication slowly enters the bloodstream at the chronic pain spot and then penetrates the central nervous system, delivering the pain relief reported by self-medicating patients.”

Cannabis Science plans to continue to grow its distribution network. The company announced that it will add Kush Factory in Los Angeles, California, as CBIS’ newest Spotlight Dispensary for the month of July 2017. As Spotlight Dispensary for the month, Kush Factory will be the first to carry the Chronic Pain CBIS Transdermal Patches.

Reference;https://fibromyalgianewstoday.com/2017/06/23/first-cannabinoid-based-patch-for-fibromyalgia-other-chronic-pain-is-ready-for-release/

Leave a Reply

Your email address will not be published. Required fields are marked *